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Abstract
Middle East Respiratory syndrome (MERS) first emerged in Saudi Arabia in 2012 and
remains a global health concern. The objective of this study was to compare the clinical fea-
tures and risk factors for adverse outcome in patients with RT-PCR confirmed MERS and
in those with acute respiratory disease who were MERS-CoV negative, presenting to the
King Fahad Medical City (KFMC) in Riyadh between October 2012 and May 2014. The
demographics, clinical and laboratory characteristics and clinical outcomes of patients with
RT-PCR confirmed MERS-CoV infection was compared with those testing negative
MERS-CoV PCR. Health care workers (HCW) with MERS were compared with MERS
patients who were not health care workers. One hundred and fifty nine patients were eligi-
ble for inclusion. Forty eight tested positive for MERS CoV, 44 (92%) being hospital
acquired infections and 23 were HCW. There were 111 MERS-CoV negative patients with
acute respiratory illnesses included in this study as “negative controls”. Patient with con-
firmed MERS-CoV infection were not clinically distinguishable from those with negative
MERS-CoV RT-PCR results although diarrhoea was commoner in MERS patients. A high
level of suspicion in initiating laboratory tests for MERS-CoV is therefore indicated. Vari-
ables associated with adverse outcome were older age and diabetes as a co-morbid illness.
Interestingly, co-morbid illnesses other than diabetes were not significantly associated with
poor outcome. Health care workers with MERS had a markedly better clinical outcome
compared to non HCW MERS patients.
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Introduction
MERS coronavirus (MERS-CoV)was initially identified in a 60-year-old male with severe pro-
gressive fatal pneumonia in Jeddah, Saudi Arabia in June 2012 [1]. As of July 24th, 2016, 1,782
patients have been confirmedwith MERS-CoV infection globally with 634 fatalities [2]. MERS
still remains a zoonotic infectionwith dromedary camels suspected to be the source of infection
[3,4]. However, transmission between humans can occurwithin family or health care settings,
some of these leading to hundreds of infections, as occurred in Jeddah, Riyadh and the Repub-
lic of Korea [5]. Outbreaks within health care facilities have been associated with low clinical
suspicion and delayed recognition, leading to unsuspected secondary transmission. Other fac-
tors predisposing to such transmission events include over-crowded emergency rooms, lack of
effective triage at first contact with the health care system, deficiencies in routine infection con-
trol practices and mild unrecognised infections, especially among health care workers (HCW)
resulting in outbreaks [5,6,7,8].
Earlier studies have attempted to describe the clinical features of MERS as well as compare
it with SARS [9, 10, 11]. However, there is still a paucity of data comparing the clinical presen-
tation of MERS with those of patients who were suspected of MERS but testedMERS-CoVneg-
ative. Information on whether or not there are clinical, demographic or epidemiological
characteristics that distinguishMERS from other causes of acute respiratory illness (ARI) is
important for clinicians providing care in MERS-CoV endemic countries such as Saudi Arabia,
or when caring for travellers returning fromMERS-endemic areas. In one study, 17 patients
with MERS were compared with 82 concurrently investigated patients who were RT-PCR neg-
ative for MERS [12]. Furthermore, while there have been reports on the clinical presentation of
MERS in HCW [13], we could not identify previous studies that compared the clinical features
of MERS-CoV infected health care workers with those who are non-health care workers.
To address these gaps in knowledge, in this study we sought to analyse the demographic
characteristics, clinical data and outcomes of all patients meeting the case definition for MERS
at a major hospital in Riyadh between 2012 and 2014 who were tested by RT-PCR for MERS-
CoV. The clinical features and outcomes of those virologically confirmed to beMERS-CoV
positive and negative were compared. In addition, we compared MERS-CoVpositive HCW
withMERS-CoVpositive non-HCWs. The molecular epidemiology of a subset of these
patients has been previously reported [7].
Methods
Clinical Setting
The study was conducted at King Fahad Medical Centre (KFMC), a 1200-bed tertiary care hos-
pital in Riyadh which comprises of four hospitals (Main, Women’s Specialized,Childrens’ and
Rehabilitation); the main hospital houses four affiliated centres (National Neurosciences Insti-
tute, Comprehensive Cancer, Diabetes and Endocrine) in addition to the Medical and Surgical
Specialty departments within the same campus. The intensive care unit (ICU) is located in the
main hospital. The medical city serves as a tertiary referral centre for patients from throughout
the Kingdom.
Patients and Specimens
Included in this study are patients who met the clinical case definition for MERS and were
tested by RT-PCR for MERS-CoVRNA betweenOctober 2012 and May 2014. A confirmed
case of MERS was defined by the Ministry of Health, Saudi Arabia as a febrile patient with ARI
who tested positive for MERS-CoV infection. Patients with community- or nosocomially-
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acquiredMERS as well as HCW diagnosedwith MERS at KFMCwere included. Patients meet-
ing the clinical case definition during the same time frame who were MERS-CoVnegative
served as controls. Nasopharyngeal swabs or lower respiratory tract specimens (tracheal aspi-
rates, bronchoalveolar lavage) were collected from patients meeting the clinical case definition
of MERS and tested for presence of MERS-CoVRNA.
Laboratory Diagnosis
From October 2012 to April 2014, samples were tested for MERS-CoV at the MOH laborato-
ries. At the end of April 2014 when in-houseMERS-CoV testing capability was developed, all
samples were tested at KFMC. RT-PCR diagnosis for MERS-CoVwas based onWHO recom-
mendations, testing the upstream and using Orf1a for confirmation [14].
Demographic and Clinical Data
Patient demographic and clinical data were retrieved from electronic health records and via
retrospective chart review.
Statistical Analysis
We compared various characteristics among MERS-CoVpositive HCW, MERS-CoVpositive
non-HCW, and MERS-CoVnegative, cases, by Fisher’s exact test for categorical factors or by
ANOVA for continuous factors. We looked at factors associated with poor outcome (admis-
sion to ICU or death) among MERS patients, and compared the factors between patients with
poor versus favourable outcome by Fisher’s exact test or ANOVA. In addition, we looked at
the factors associated with death in MERS patients by fitting a logistic regression.We investi-
gated time from hospital admission to death among subgroups, by fitting Kaplan-Meier curves,
and compared subgroups by the log-rank test.
Ethical Issues
The study was approved by the King Fahad Medical City Institutional Review board. Given
that this was an outbreak situation they waived the requirement for individual informed
consent.
Results
The demographic characteristics of 159 eligible patients were reviewed. Forty eight of the
patients were confirmed to beMERS-CoVRT-PCR positive while 111 were negative in
MERS-CoVRT-PCR tests (Table 1). Of the 48 MERS patients, 44 were hospital acquired and
23 HCW. Health care workers with MERS were more likely to be expatriates than MERS-CoV
infected non-HCW (p<0.01) or MERS-CoVnegative (p<0.01) patients. However, there was
no difference between non-HCWMERS-CoVpositive and MERS-CoVnegative patients in
this regard. Of the 23 HCWwith MERS, 21 were from the Philippines, one was fromMalaysia
and one from India. AlthoughMERS-CoVpositive patients were overall more likely to be
female (68.8% vs 49.6%; p = 0.04), the non-HCWMERS-CoVpositive patients were not signif-
icantly different in this regard fromMERS-CoVnegative patients (56.3% vs 49.6%; p = 0.28).
MERS patients who were non-HCWwere more likely to be older (median age 60 years) than
non-MERS patients (median age 33 years) (p<0.01) and HCWMERS patients (median age 36
years)(p = 0.01). The non HCWMERS patients were all persons who had been attended the
hospital emergency room or those who were admitted for other reasons and acquired infection
within the hospital.
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A history of exposure to animals (camel, dog or poultry) was more common in the MERS-
CoV positive patients overall, compared with MERS-CoVnegative patients (p = 0.04)
(Table 2). A history of exposure to ill persons in a health care setting in the two weeks prior to
onset of illness was more frequent in non- HCWMERS-CoVpositive (95%) than in MERS-
CoV negative (62%) patients (p = 0.01).
The presenting clinical features and co-morbidities of MERS-CoVpositive (HCW and non-
HCW) and MERS-CoVnegative patients are shown in Table 3. Comparatively, MERS-CoV
positive (HCW and non-HCW and negative patients had similar clinical presentations and co-
morbidities, except for diarrhoea that was more frequent in the MERS-CoVpositive cohort.
The frequency of reporting diarrhoea in the MERS-CoVpositive HCW, MERS-CoVpositive
non-HCW andMERS-CoVnegative patient groups was 11/23 (50%), 5/25 (23%) and 15/111
(16%) respectively. A statistically significant difference was observedwhen the frequency of
diarrhoeawas compared between the MERS-CoVpositive patients (either HCW or non-
HCW) and MERS-CoVnegative patients (p = 0.02). Within the MERS-CoVpositive cohort,
shortness of breath, tachycardia and underlying co-morbidities (such as cancer, diabetes,
hypertension and heart disease) were significantlymore frequent amongst non-HCWs than in
HCWs.
Table 1. Demographics of MERS positive HCW, MERS positive non-HCW and MERS negative cases.
1.Positive HCW
cases (N = 23)
2.Positive non-
HCW cases
(N = 25)
3.Negative cases
(N = 111)
p-value (1 vs 2) p-value (2 vs 3) p-value (1+2 vs 3)
n (%) n (%) n (%)
Age group, in years <0.01 0.04 <0.01
0–20 0 (0%) 1 (4%) 34 (31%)
21–30 3 (13%) 3 (12%) 13 (12%)
31–40 12 (52%) 3 (12%) 16 (14%)
41–50 4 (17%) 1 (4%) 9 (8%)
51–60 3 (13%) 5 (20%) 14 (13%)
>60 1 (4%) 12 (48%) 25 (23%)
Median (range) 36 (24–74) 60 (12–77) 33 (0–91) 0.01 <0.01 0.02
Male 6 (26%) 9 (36%) 56 (50%) 0.67 0.28 0.04
Saudi 1 (4%) 24 (96%) 101 (91%) <0.01 0.69 <0.01
doi:10.1371/journal.pone.0165978.t001
Table 2. Comparison of potential exposure factors among the three patient groups.
Characteristics 1.Positive HCW
cases (N = 23)
2.Positive non-
HCW cases
(N = 25)
3.Negative
cases (N = 111)
p-value (1 vs 2) p-value (2 vs 3) p-value (1+2 vs 3)
N (%) n (%) n (%)
Travel history 0 (0%) 1 (5%) 14 (15%) 0.48 0.30 0.04
Animal exposure history# 1 (4%) 2 (10%) 0 (0%) 0.59 0.04 0.04
Exposed to a health care setting* 23 (100%) 21 (95%) 58 (62%) 0.98 0.01 <0.01
Exposure duration >0.99 0.04 0.01
0-4hr 6 (26%) 5 (23%) 45 (50%)
> = 5hrs 17 (74%) 17 (77%) 45 (50%)
*-two weeks prior to onset of illness
# Animal exposure of HCW was to a dog and of non-HCW with MERS was to a camel and poultry
doi:10.1371/journal.pone.0165978.t002
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The biochemical and haematologic parameters between the three groups were similar,
except for higher white blood count (WBC) values in MERS-CoVnegative patients and higher
serum creatinine levels in MERS-CoVpositive non-HCW compared with MERS negative
patients (Table 4). There was no significant difference between the laboratory parameters of
MERS-CoVpositive HCW and non-HCW.
Among the 48 patients with confirmedMERS, 47 had chest radiography available for review.
Of these, 12 (25%) had normal chest radiographs at initial presentation, 21 (45%) had unilateral
lung infiltrates and 14 (30%) had bilateral lung infiltrates. Seven (15%) of the total cohort never
developed an infiltrate. Amongst those with normal initial radiographs, 3 (25%) and 2(17%)
deteriorated and developed unilateral and bilateral infiltrates, respectively. Amongst patients
with baseline unilateral infiltrates, 15 (71%) progressed and developed bilateral infiltrates; 4
(19%) had no changes. Two patients with bilateral infiltrates survived and had their lungs revert
to normalcy.
Table 3. Comparison of clinical symptoms and co-morbidity status among the three patient groups.
1. Positive
HCW cases
(N = 23)*
2. Positive non-
HCW cases
(N = 25)*
3. Negative
cases
(N = 111)*
p-value (1 vs 2) p-value (2 vs 3) p-value (1+2 vs 3)
n (%) n (%) n (%)
Sign & Symptoms
Fever 20 (87%) 24 (96%) 90 (81%) 0.54 0.13 0.15
Sore throat 7 (32%) 9 (45%) 18 (21%) 0.58 0.05 0.06
Cough 14 (64%) 20 (83%) 91 (86%) 0.24 >0.99 0.12
Dyspnoea 6 (26%) 19 (83%) 63 (64%) <0.01 0.13 0.38
Hemoptysis 1 (4%) 1 (5%) 9 (10%) >0.99 0.74 0.48
Wheezing 3 (13%) 6 (29%) 19 (20%) 0.37 0.60 >0.99
Tachycardia 1 (4%) 14 (61%) 40 (42%) <0.01 0.17 0.37
Abdomen pain 7 (32%) 6 (27%) 19 (21%) >0.99 0.70 0.35
Vomiting 5 (23%) 8 (33%) 25 (27%) 0.64 0.76 >0.99
Diarrhea 11 (50%) 5 (23%) 15 (16%) 0.12 0.67 0.02
Headache 9 (39%) 6 (27%) 17 (19%) 0.60 0.58 0.11
Runny nose 4 (18%) 6 (27%) 17 (19%) 0.72 0.55 0.75
Nausea 4 (17%) 5 (23%) 9 (10%) 0.94 0.20 0.17
Co-morbidity
Cancer 0 (0%) 9 (38%) 15 (15%) <0.01 0.03 0.71
Obesity 4 (17%) 8 (33%) 18 (18%) 0.36 0.18 0.42
Smoking 1 (4%) 1 (5%) 8 (9%) >0.99 0.89 0.62
Diabetes 3 (13%) 14 (58%) 38 (37%) <0.01 0.10 >0.99
HIV/other immune deficiency disease 0 (0%) 8 (35%) 16 (16%) 0.01 0.07 0.92
Steroid use 0 (0%) 1 (5%) 3 (3%) 0.98 >0.99 0.99
Hypertension 5 (22%) 15 (62%) 37 (37%) 0.01 0.04 0.61
Heart disease 0 (0%) 11 (46%) 31 (31%) <0.01 0.24 0.47
Asthma 4 (17%) 3 (12%) 22 (22%) 0.95 0.46 0.45
CLD 0 (0%) 4 (17%) 7 (7%) 0.12 0.24 0.97
Haematological disorder 0 (0%) 4 (17%) 20 (20%) 0.12 >0.99 0.15
Pregnancy 0 (0%) 0 (0%) 4 (4%) - 0.80 0.44
*Data on all clinical features were not available on all patients. % calculated based on denominator for which data was available.
doi:10.1371/journal.pone.0165978.t003
Comparative Study of MERS and Other Acute Respiratory Diseases
PLOS ONE | DOI:10.1371/journal.pone.0165978 November 3, 2016 5 / 12
Adverse clinical outcomes such as ICU admission or death were not significantly different
betweenMERS-CoVpositive (HCW and non-HCW considered together) and MERS-CoV
negative patients. However, of the MERS-CoVpositive HCW, only 4 of 23 (17%) required ICU
admission and 1 of 23 (4.35%) died in contrast with 21 of 25 (84%) (p<0.001) and 16 of 25
(60%) (p<0.001) of the non-HCWs with MERS-CoV infection, respectively. Furthermore,
non-HCWMERS-CoVpositive patients were more likely to be admitted to ICU (21 of 25;
84%) than MERS-CoVnegative patients (62 of 111 (56%) (p = 0.02); and were more likely to
die (16 of 25; 60%) than MERS-CoVnegative patients (25 of 111; 23%) (p<0.001) (Table 5).
Among the patients with MERS-CoV infection, a poor clinical outcome (ICU admission or
death) was significantly associated with older age, presence of co-morbid conditions, lower
lymphocyte count, higher neutrophil count, higher serum creatinine and higher serumLDH
levels, by univariate analysis (Table 6). Diabetes was the co-morbid condition most strongly
associated with adverse outcome (p = 0.0002). In multivariate regression analysis, factors that
remained associated with a decreased risk of death were younger age and being a HCW
(Table 7).
Using Kaplan-Meier analysis, survival was shown to be significantly different in patients
with MERS-CoV infection (taken together) in comparison with MERS-CoVnegative patients
(Fig 1 upper panel). When MERS-CoVpositive patients were stratified as HCW and non-
HCWs, the former had better clinical outcome compared with non-HCW (p = 0.003) (Fig 1
lower panel). MERS positive non-HCW had worse outcome that MERS negative patients
(p<0.001). Survival time was not significantly different betweenMERS-CoVpositive HCW
andMERS-CoVnegative patients (p = 0.45). Survival analysis confirmed than MERS patients
without co-morbidities had markedly better survival than those with diabetes (p = 0.01), but
there was no significant difference compared with patients with co-morbidities other than
Table 4. Comparison of laboratory parameters among three patient groups.
1.Positive HCW cases
(N = 23)
2.Positive non-HCW
cases (N = 25)
3.Negative cases
(N = 111)
p-value (1 vs 2) p-value (2 vs 3) p-value (1+2 vs 3)
μ (95% CI) μ (95% CI) μ (95% CI)
WBC 6.3 (4.7, 7.9) 7.5 (5.9, 9.1) 11.1 (9.6, 12.6) 0.30 0.03 <0.01
Lymphocyte 28.8 (23.9, 33.6) 21.6 (13.9, 29.3) 21.9 (19.1, 24.7) 0.16 0.93 0.29
Neutrophils 58.9 (50.5, 67.4) 69.6 (61.0, 78.3) 67.3 (63.6, 71.0) 0.09 0.60 0.49
Creatinine 70.0 (50.1, 90.0) 170.1 (78.3, 261.9) 103.1 (83.5, 122.7) 0.07 0.03 0.34
Creatine-k* 68.8 (-15.0, 152.6) 104.5 (-22.8, 231.8) 59.7 (28.5, 90.8) 0.78 0.33 0.37
Platelet count 254.1 (210.4, 297.8) 208.6 (156.6, 260.7) 264.3 (238.9, 289.8) 0.21 0.06 0.13
APTT 44.1 (39.9, 48.3) 44.0 (39.9, 48.1) 40.6 (38.4, 42.8) 0.97 0.17 0.10
LDH* 464.1 (354.4, 573.7) 516.1 (437.6, 594.7) 1368.7 (-249.0, 2986.5) 0.44 0.56 0.45
* Including some extreme large values.
doi:10.1371/journal.pone.0165978.t004
Table 5. Comparison of poor outcome among three patient groups.
1.Positive HCW
cases (N = 23)
2.Positive non-
HCW cases
(N = 25)
3.Negative cases
(N = 111)
p-value (1 vs 2) p-value (2 vs 3) p-value (1+2 vs 3)
n (%) n (%) n (%)
Admission to ICU 4 (17%) 21 (84%) 62 (56%) <0.01 0.02 0.79
Died 1 (4.3%) 16 (64%) 25 (23%) <0.001 <0.001 0.12
doi:10.1371/journal.pone.0165978.t005
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diabetes (p = 0.54). Finally, MERS patients with diabetes had significantly worse survival that
those with co-morbidities other than diabetes (p = 0.01) (Fig 2).
Discussion
Clinical, demographic and outcome data from 159 patients investigated as suspectedMERS
were analysed; of these 48 were virologically confirmed as MERS-CoV infected.MERS patients
who were not HCWwere older than HCW and those who were MERS-CoVnegative. The pre-
senting clinical features of patients with MERS were indistinguishable from those who were
investigated for MERS but found MERS-CoVnegative, with the exception that diarrhoeawas
more common in patients with MERS. This appears to be primarily because 11 of 23 (48%)
HCWwithMERS reported diarrhoea significantlymore often than patients who were MERS-
CoV negative (15/94; 16%) (p = 0006). However, there was no difference in the frequency of
diarrhoea in non-HCWMERS patients and non-MERS patients. Notably, diarrhoea was also a
prominent feature of SARS with evidence of virus replication in intestinal epithelium [15]. It is
Table 6. Factors associated with poor outcome (admission to ICU or death) among 48 MERS patients.
Poor outcome (N = 25) Favorable outcome (N = 23) p-value
μ (95% CI) μ (95% CI)
Age (yr) 53.8 (46.7, 61.0) 39.5 (34.5, 44.5) <0.01
Age (median, range) 60 (12, 77) 36 (22, 64) <0.01
WBC (x109/L) 7.5 (6.0, 9.0) 6.3 (4.6, 7.9) 0.29
Lymphocytes (x109/L) 19.2 (14.0, 24.5) 31.7 (23.8, 39.6) 0.01
Neutrophils (%) 72.7 (66.1, 79.4) 55.1 (45.2, 64.9) <0.01
Creatine (μmol/L) 176.3 (84.5, 268.2) 62.2 (55.5, 69.0) 0.04
Creatine-kinase (U/L)* 103.9 (-5.2, 213.0) 21.5 (20.5, 22.5) 0.65
Platelet count (x109/L) 209.4 (162.5, 256.3) 253.1 (200.9, 305.3) 0.23
APTT (secs) 45.8 (41.6, 50.0) 40.3 (37.4, 43.3) 0.10
LDH (U/L)* 566.8 (487.3, 646.4) 369.8 (300.0, 439.6) <0.01
n (%) n (%) p-value
Age >60yr 11 (44%) 2 (9%) 0.02
No comorbid disease 3 (12%) 10 (43%) <0.01
Diabetes with or without any other comorbid disease 15 (60%) 2 (9%)
Any other comorbid disease without diabetes 7 (28%) 11 (48%)
doi:10.1371/journal.pone.0165978.t006
Table 7. Factors associated with fatal outcome in 48 MERS cases.
Characteristics Risk of death
Adjusted OR (95% CI)
Age group, in years
0–45 1.00
46–65 8.83 (1.26, 62.06)
65+ 19.65 (1.39, 278.81)
Female 1.00
Male 0.65 (0.08, 5.35)
Other occupation 1.00
Heath care workers 0.12 (0.01, 0.91)
No comorbid disease 1.00
With any comorbid disease 1.03 (0.06, 16.39)
doi:10.1371/journal.pone.0165978.t007
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Fig 1. Time from hospital admission to death. A: Comparing patients with MERS-CoV infection (red line) and those
negative for MERS-CoV (black line) (p = 0.01). B: Comparing health care workers with MERS CoV (red dotted line; group1),
non-HCW with MERS (red solid line; group 2) and patients without MERS-CoV infection (black solid line; group 3). Log rank
test group 1 vs. group 2 p = 0.003; group 2 vs group 3 p = 0.45; group 1 vs group 3 p<0.001.
doi:10.1371/journal.pone.0165978.g001
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important to note that 25% of patients had normal chest radiographs at initial presentation
and 15% never developed an infiltrate. This was reminiscent of the radiological presentation of
SARS where a proportion of patients also did not have an infiltrates on chest radiography at
presentation but many of these did have detectable abnormalities on computerised tomogra-
phy scans [15]. The observation that the clinical features of patients with MERS-CoV infection
is indistinguishable from those who are hospitalised for other ARI emphasises the need for a
low threshold of clinical suspicion for initiatingMERS-CoV laboratory testing in patients with
severe respiratory disease. Exposure to hospital environments in the two weeks prior to clinical
onset was one significant risk factor for infection.However, 62% of patients who were not
MERS-CoVpositive also had similar exposure to health care facilities, possibly becausemany
of them had other co-morbidities. Exposure to animals, though significantlymore common
reported in the non HCW patients with MERS (10%) than in those without MERS (0%), was
not elicited in the majority of patients with MERS. Some of the MERS-CoV infections (both
HCW and non-HCW) were known to have been acquired nosocomially [7] and thus would
not be expected to have zoonotic exposure as a source of infection.
Patients with MERS who were non-HCWwere more likely to> 50 years of age when com-
pared to non-MERS patients (p = 0.0034) and MERS patients who were HCW (p = 0.0005).
Patients with MERS who were non-HCW had significantly worse clinical outcomes than those
who were MERS-CoVnegative or HCWwithMERS-CoV infection. This may be related, in
part, to the fact that both HCW and non-MERS patient groups were younger and had fewer
co-morbid conditions. In a previous report of MERS-CoV infection in HCW detected by active
Fig 2. Time from hospital admission to death stratified by comorbid disease status among MERS positive cases.
Survival analysis was carried out to ascertain impact of co-morbidities on survival in patients with MERS-CoV infection.
Black line (group 1): No comorbid disease; Red line (group 2): Diabetes with or without other comorbidities; Green line
(group 3): Any other comorbid disease without diabetes. Log rank test: group 1 vs group 2 p = 0.01; Group 1 vs. group 3
p = 0.54; group 2 vs. group 3 p = 0.01.
doi:10.1371/journal.pone.0165978.g002
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case finding of contacts, seven infectedHCWwere documented, two of whom were asymp-
tomatic, while the other five had mild upper respiratory tract symptoms [13]. The age of the
HCWwithMERS-CoV infection ranged between 28–56 years with only one of them having
underlying co-morbidity. Only 4 (17%) required ICU admission and one (4%) died. In other
case series of MERS, significant proportions have beenHCW, but the clinical features of the
HCW and non HCWMERS patients have not been systematically compared [6,8,16]. It is
clear that the overall clinical presentation and outcomes in HCW and non-HCWMERS is
markedly different.When analysing clinical outcomes of MERS, it is important to distinguish
between those in HCW and non-HCW, because they have markedly different clinical
outcomes.
Taking all MERS patients together, the variables associated with poor clinical outcomes in
univariate analysis were older age, presence of co-morbid illness, neutrophilia, lower lympho-
cyte counts, higher serum creatinine levels and higher serumLDH levels. On multivariate
regression analysis, only occupation (HCW) and younger age were significantly associated
with favourable clinical outcome. In survival analysis, MERS patients with diabetes (with or
without other co-morbidites) had worse survival than MERS patients with other co-morbidi-
ties (other than diabetes) or those with no co-morbidities. Interestingly, patients with co-mor-
bidities other than diabetes were not significantly different to those with no co-morbidities.
Limitations of the study include the possibility that some patients with MERS-CoVmay
have beenmissed because of false negative RT-PCR results and may be categorised as non-
MERS-CoVpatients. Convalescent sera were not available for testing from all patients under
investigation. Secondly, the data collectionwas retrospective. Viral load data was not available
for analysis. The MERS negative cases are likely to be heterogeneous in their diagnosis. Final
discharge diagnosis of this control group is unfortunately not available.
In conclusion, MERS could not be reliably distinguished from patients who were MERS
negative by clinical, demographic or epidemiological criteria; this highlights the need for a high
index of suspicion, early isolation and early laboratory testing to identify infected patients and
prevent nosocomial spread. An important observation from this study is that HCWwith
MERS had a markedly more favourable clinical outcome compared with MERS patients who
were non-HCW, primarily because they were younger and had less co-morbidities. Clinical
progression, presentation and outcomes are very different in these two groups and this has to
be kept in mind and adjusted for when therapeutic trials for MERS are designed. Diabetes,
rather than other co-morbidities had a significant adverse impact on survival.
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